Data availability
The data supporting the findings of this study are available within the article and the main figures or its supplementary materials. Raw data used to generate plots are available from the corresponding authors upon reasonable request.
References
-
Yang, S. et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect. Dis. 24, e70–e72 (2024).
-
Jeworowski, L. M. et al. Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023. Eurosurveillance 29, 2300740 (2024).
-
Kurhade, C. et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat. Med. 29, 344–347 (2023).
-
Szabo, P. A., Miron, M. & Farber, D. L. Location, location, location: Tissue resident memory T cells in mice and humans. Sci. Immunol. 4, eaas9673 (2019).
-
Russell, M. W. & Mestecky, J. Mucosal immunity: the missing link in comprehending SARS-CoV-2 infection and transmission. Front. Immunol. 13, 957107 (2022).
-
Lavelle, E. C. & Ward, R. W. Mucosal vaccines—fortifying the frontiers. Nat. Rev. Immunol. 22, 236–250 (2022).
-
Wang, S. et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct. Target. Ther. 8, 149 (2023).
-
Madhavan, M. et al. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: an open-label partially-randomised ascending dose phase I trial. eBioMedicine 85, 104298 (2022).
-
Li, J.-X. et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir. Med. 10, 739–748 (2022).
-
Wu, S. et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat. Commun. 11, 4081 (2020).
-
Arnberg, N. Adenovirus receptors: implications for tropism, treatment and targeting. Rev. Med. Virol. 19, 165–178 (2009).
-
de Graaf, M. & Fouchier, R. A. M. Role of receptor binding specificity in influenza A virus transmission and pathogenesis. EMBO J. 33, 823–841 (2014).
-
Ge, S. & Wang, Z. An overview of influenza A virus receptors. Crit. Rev. Microbiol. 37, 157–165 (2011).
-
Chen, J. et al. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Sci. Bull. 67, 1372–1387 (2022).
-
Zhang, L. et al. Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters. Nat. Commun. 14, 4117 (2023).
-
Zhu, F. et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir. Med. 18, 749–760 (2022).
-
Zhu, F. et al. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 11, 1075–1088 (2023).
-
Wang, C. C. et al. Airborne transmission of respiratory viruses. Science 373, eabd9149.
-
Bull, J. J., Smithson, M. W. & Nuismer, S. L. Transmissible Viral Vaccines. Trends Microbiol. 26, 6–15 (2018).
-
Marin, M., Leung, J. & Gershon, A. A. Transmission of vaccine-strain varicella-zoster virus: a systematic review. Pediatrics 144, e20191305 (2019).
-
Lopez Moreno, G., Nirmala, J., Goodell, C., Culhane, M. & Torremorell, M. Shedding and transmission of a live attenuated influenza A virus vaccine in pre-weaned pigs under field conditions. PLoS ONE 16, e0246690 (2021).
-
Treanor, J. History of live, attenuated influenza vaccine. J. Pediatr. Infect. Dis. Soc. 9, S3–S9 (2020).
-
Ledford, H. Spate of polio outbreaks worldwide puts scientists on alert. Nature 609, 20–21 (2022).
-
Thangavel, R. R. & Bouvier, N. M. Animal models for influenza virus pathogenesis, transmission, and immunology. J. Immunol. Methods 410, 60–79 (2014).
-
Nguyen, T.-Q., Rollon, R. & Choi, Y.-K. Animal models for influenza research: strengths and weaknesses. Viruses 13, 1011 (2021).
-
Bouvier, N. M. & Lowen, A. C. Animal models for influenza virus pathogenesis and transmission. Viruses 2, 1530–1563 (2010).
-
Stauft, C. B. et al. Intranasal or airborne transmission-mediated delivery of an attenuated SARS-CoV-2 protects Syrian hamsters against new variants. Nat. Commun. 14, 3393 (2023).
-
Knisely, J. M. et al. Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report. npj Vaccines 8, 53 (2023).
-
Mohn, K. G. I., Smith, I., Sjursen, H. & Cox, R. J. Immune responses after live attenuated influenza vaccination. Hum. Vaccines Immunother. 14, 571–578 (2018).
-
Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl. Acad. Sci. USA 117, 16587 (2020).
Acknowledgements
Diagrams were created with BioRender.com. This work was supported by the National Program on Key Research Project of China (2023YFC2307800 and 2023YFC3042900), the National Natural Science Foundation of China (82041038, 32000649), Natural Science Foundation of Fujian Province (2021J02006), Science and Technology Project of Xiamen City (2022CXY0108), the Fundamental Research Funds for the Central Universities (20720220006), the Open Research Fund of State Key Laboratory of Vaccines for Infectious Diseases (2024SKLVDkf02), and Research Fund of Xiang An Biomedicine Laboratory (2024XAKJ0101002).
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Chen, Y., Zhang, L., Chen, C. et al. Airborne transmission-mediated delivery of a live-attenuated influenza virus vector-based intranasal COVID-19 vaccine protects Syrian hamsters against SARS-CoV-2 challenge. npj Vaccines (2025). https://doi.org/10.1038/s41541-025-01332-5
-
Received:
-
Accepted:
-
Published:
-
DOI: https://doi.org/10.1038/s41541-025-01332-5
